Kardiologie Ebreichsdorf - Univ. Doz. Dr. Martin Haas, MSc

2483 Ebreichsdorf, Hauptplatz 22 | Telefon: 0699 / 12 543 657

Publikationsliste Univ. Doz. Dr. Martin Haas, MSc


  1. Glomerular permselectivity in proteinuric patients after kidney transplantation
    Oberbauer R, Haas M, Regele H, Barnas U, Schmidt A and Mayer G
    J Clin Invest  1995; 96:22-29 
  2. The effects of prolonged substitution of recombinant human growth hormone on renal functional reserve in growth hormone deficient adults
    Riedl M, Haas M, Oberbauer R, Gisinger J, Luger A and Mayer G
    J Am Soc Nephrol. 1995;6:1434-1438.
  3. Renal function and glomerular permselectivity late after living related donor transplantation
    Borchhardt K, Yilmaz N, Haas M and Mayer G
    Transplantation 1996; 62:47-51 
  4. The effects of prolonged angiotensin converting enzyme inhibition on proteinuria and excretory kidney  function in renal allograft recipients in the late posttransplant period
    Barnas U, Schmidt A, Haas M, Oberbauer R and Mayer G
    Nephrol Dial Transplant 1996; 11:1822-24
  5. Atubular glomeruli in patients with chronic allograft rejection
    Pagtalunan ME, Oberbauer R, Haas M, Barlan M, Mayer G, Olson JL, Meyer TW
    Transplantation 1996; 61:1166-71
  6. A multilocular B-cell neoplasia presenting as multiple myeloma and polymorphic lymphoma of recipient origin 2 months after kidney transplantation in a heart transplant recipient.
    Haas M, Mannhalter C, Ullrich R, Schwarzinger I, Zuckermann A, Derfler K and Jager U
    Nephrol Dial Transplant 1996; 11:2085-87 
  7. Cyclosporin A associated hypertension: pathomechanism and clinical consequences
    Haas M and Mayer G
    Nephrol Dial Transplant 1997; 12:395-398
  8. Interferon alfa-2c and proteinuria in a patient with focal and segmental glomerulosclerosis
    Haas M, Jager U and Mayer G
    Lancet 1997; 349:1147-48
  9. Parameters associated with chronic renal transplant failure
    Barnas U, Schmidt A, Haas M, Kaider A, Tillawi S, Wamser P and Mayer G.
    Nephrol Dial Transplant 1997; 12 Suppl2: 82-85
  10. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients
    Borchhardt K, Haas M, Yilmaz N, Oberbauer R, Schmidt A, Barnas U 
    and Mayer G
    Kidney Int  1997; 52: 1622-25
  11. Angiotensin converting enzyme insertion/deletion polymorphism and short term renal response to ACE inhibition: Role of sodium status
    van der Kleij-FGH, Schmidt A, Navis GJ, Haas M, Yilmaz N, deJong PE, Mayer G and deZeeuw D
    Kidney Int 1997; Suppl.63: S23-26
  12. The angiotensin converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease
    Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll H, Kramar R, Auinger M, Graf H , Schneider B and Mayer G for the Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease
    Kidney Blood Press Res. 1998;21:66-69.
  13. Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulosclerosis
    Haas M, Oberbauer R, Yilmaz  N, Borchhardt K, Regele H, Druml W and  Mayer G
    Nephrol Dial Transplant 1998; 13: 2013-6
  14. A patient with antiphospholipid antibodies developing Wallenberg Syndrome during plasmaseparation
    Haas M, Oberbauer R, Druml W, Mayer G
    Nephrol Dial Transplant 1998;13:3261-2
  15. The spectrum of acute renal failure in tumor lysis syndrome
    Haas M, Öhler L, Böhmig GA, Watzke H, Prokesch R and Druml W
    Nephrol Dial Transplant. 1999;14:776-9
  16. Heart transplantation or combined heart/kidney transplantation? Even one renal biopsy may fool you
    Haas M, Kain R, Mayer G, Oberbauer R
    Nephrol Dial Transplant. 1999;14:1014-5
  17. Hypothyroidism as a cause of tacrolimus intoxication and acute renal failure: a case report
    Haas M, Kletzmayr J, Staudinger Th, Böhmig GA, Mayer G, Leko-Mohr Z,
    Druml W
    Wien Klin Wochenschr 2000; 21:939-941
  18. Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy
    Oberbauer R, Nessov V, Weidekamm C, Haas M, Szerkeres Th, Mayer G
    Exp Nephrol. 2001;9(1):49-53
  19. Leucocyte scintigraphy with 99mTc-Exametazime-labeled leukocytes is not useful for follow up-up of systemic vasculitis
    Becherer A, Deicher R, Jilma B, Haas M, Staudenherz A, Hörl WH, Dudzak R, Kletter K
    Wien Klin Wochenschr 2002;15:114(1-2):28-32
  20. The LDH-ratio as a marker for response to plasma exchange in HUS/TTP of the adult
    Haas M, Leko-Mohr Z, Lang Th, Jansen M, Knöbl P, Hörl WH, Druml W
    Clin Nephrol 2002;57(6):414-420
  21. Osteoprotegerin as marker of  high turnover osteodystrophy and decreased bone mineralization in hemodialysis patients
    Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz Ch, Domenig Ch, Zsontsich Th, Klaushofer K, Delling G, Oberbauer R
    Am J Kidney Dis  2002;39(3):580-586
  22. Treatment of therapy resistant idiopathic membranous nephropathy with probucol: a pilot study
    Haas M, Mayer G, Wirnsberger W, Holzer H, Ratschek M, Neyer U, Neuweiler J, Kramar R, Schneider B, Breiteneder-Geleff S,  Regele HM, Hörl WH, Kerjaschki D
    Wien Klin Wochenschr 2002;114/4:143-147
  23. Long-term treatment of myasthenia gravis by immunoadsorption
    Haas M, Mayr N, Zeitlhofer J, Goldammer A, Derfler K
    Journal of Clinical Apheresis 2002; 17(2):84-87
  24. Influence of plasma immunoglobulin level on antibody synthesis
    Goldammer A, Derfler K, Herkner K, Bradwell AR, Hörl WH, and Haas M
    Blood 2002;100(1):353-355
  25. Peri-operative immunoadsorption in sensitized renal retransplant recipients
    Haas M, Böhmig GA, Leko-Mohr Z, Exner M, Regele H, Derfler K, Hörl WH, and Druml W
    Nephrol Dial Transplant  2002; 17(8):1503-1508
  26. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy
    Haas M, Leko-Mohr Z, Erler C, Mayer G
    Am J Kidney Dis  2002;40(3): 458-463
  27. Zoledronic acid to prevent bone loss in the first six months after renal transplantation
    Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C,Mitterbauer C, Steininger R, Zsontsich T, Klaushofer K, Delling G, Oberbauer
    Kidney Int  2003;63 (3 ): 1130 – 1136
  28. Immunoadsorption for the treatment of  a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS 13 [letter]
    Knöbl P, Haas M , Lazcika K, Varadi K, Turecek P
    J Thromb Haemost. 2003;1(1):187-9 
  29. Maximal lipid lowering therapy of FH patients for 28 months results in reduced coronary calcium and plaque stabilization as detected by fast computed tomography.
    Hoffmann U, Derfler K, Haas M, Stadler A, Brady TJ, Kostner K
    Am J Cardiol. 2003;91(4):461-4
  30. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years
    after renal transplantation.
    Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R.
    Kidney Int. 2004;65(1):304-9
  31. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function
    Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Hörl WH, Haas M
    Am J Kidney Dis. 2004; 43(6):1065-70
  32. A rare cause of anemia due to intestinal tuberculosis in a renal transplant recipient
    Kandutsch S, Feix A, Haas M, Hafner M, Sunder-Plassmann G, Soleiman A.
    Clin Nephrol 2004;62:158-61
  33. The effect of oral anticoagulation on clotting during hemodialysis.
    Farzad Z, Benesch T, Kodras K, Neumann I, Dimopoulos-Xicki L, Haas M.
    Kidney Int. 2005; 68(2):862-6
  34. Effects of Bisphosphonates on Bone Loss in the First Year after Renal Transplantation: A Metaanalysis of Randomized Controlled Trials. Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Nephrol Dial Transplant 2006; 21(8):2275- 81
  35. Complete renal tubular acidosis late after kidney transplantation. Schwarz C, Benesch T, Kodras K, Oberbauer R, Haas M. Nephrol Dial Transplant 2006; 21(9):2615-20
  36. Changes of coronary calcification after kidney transplantation. Oschatz E, Benesch T,
    Kodras K, Hoffmann U, Haas M. Am J Kidney Dis 2006; 48(2):307-13
  37. The impact of ACE Inhibitor and Angiotensin Receptor Blocker use during postischemic acute transplant failure on renal allograft survival
    Heinze G, Collins S, Benedict MA, Nguyen L, Kramar R, Winkelmayer W, Haas M, Kainz A, Oberbauer R. Transplantation 2006; 82(11):1441-8
  38. Borchhardt K, Sulzbacher I, Benesch T, Födinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007; 7(11):2515-21 
  39. Probst P, Soleiman A, Zbornay V, Benesch T, Haas M. The effect of kidney transplantation on distal tubular vacuolar H+-ATPase.
    Transplantation 2008; 85(3):391-97
  40. Kodras K, Benesch T, Neumann I, Haas M. Comparison of two dialyzers (AN69 ST vs. FX 100) for heparin free dialysis in patients with oral anticoagulation. Blood Purif. 2008;26(3):226-30
  41. Borchhardt K, Heinzl H, Mayerwöger E, Hörl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008; 86(7):919-24
  42. Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, Haas M. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008; 8(9):1864-70
  43. Misof B, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, Kainz A, Oberbauer R, Mühlbacher F, Klaushofer K. Short-term effects of  high dose zoledronic acid treatment on bone mineralization density  distribution (BMDD) after orthotopic liver transplantation. Calcified Tissue  Int 2008;83(3):167-75
  44. Rauner M, Stupphann D, Haas M, Fert I, Glatigny S, Sipos W, Breban M, Pietschmann P. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J Rheumatol. 2009; 36:120-126
  45. Fahrleitner-Pammer A, Dobnig H, Dimai HP, Holzer H, Benesch T, Borchhardt K, Cejka D, Haas M. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. Clin Nephrol. 2009;71:652-659
  46. Borchhardt K, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassman G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 2010; 31(6):482-9
  47. Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis – associated adynamic bone disease with teriparatide (PTH(1-34)): a pilot study. Kidney Blood Press Res 2010; 33(3):221-226
  48. Goliasch G, Blessberger H, Azar D, Heinze G, Wojta J, Bieglmayer C, Wagner O, Schillinger M, Huber K, Maurer G, Haas M, Wiesbauer F. Markers of bone metabolism in premature myocardial infarction (<40 years of age). Bone 2011; 48:822-626
  49. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche H. Sclerostin and Dickkopf-1 in renal Osteodystrophy. Clin J Am Soc Nephro 2011;6(4):877-82
  50. Roth GA, Lebherz-Eichinger D, Ankersmit HJ, Hacker S, Hetz H, Vukovich T, Perne A, Reiter T, Farr A, Hörl WH, Haas M, Krenn CG. Increased total Cytokeratin-18 serum and urine levels in chronic kidney disease. Clin Chim Acta 2011; 412(9-10):713-717
  51. Magpantay L, Farzai Z, Oberbauer R, Haas M. The effect of fluid intake on chronic kidney transplant failure – a pilot study. J Renal Nutr 2011, 21(6):499-505
  52. Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch J, Kainberger F, Bohle B, Haas M. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012;27:226-230
  53. Lebherz-Eichinger D, Ankersmit HJ, Hacker S, Hetz H, Kimberger O, Schmidt EM, Reiter T, Hörl WH, Haas M, Krenn CG, Roth GA. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clin Chim Acta. 2012;413:282-86
  54. Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, Kikic Z, Krestan C, Schueller-Weidekamm C, Kainberger F, Haas M. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011 Sep;6(9):2264-71.
  55. Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014 Jan;99(1):248-55
  56. Cejka D, Weber M, Diarra D, Reiter T, Kainberger F, Haas M. Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease. Bone. 2014 Jul;64:33-8.
  57. Bielesz B, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH Bieglmayer C, Sunder-Plassmann G. Correlations and Time Course of FGF23 and Markers of Bone Metabolism in Maintenance Hemodialysis Patients. Clin Biochem. 2014 Sep;47(13-14):1316-9.
  58. Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D. Sclerostin Declines during Hemodialysis and Appears in Dialysate. Blood Purif. 2014 Sep 13;38(1):30-36.


  1. Proteinuria as a consequence of altered glomerular permselectivity – Clinical implications
    Oberbauer R, Haas M and Mayer G
    Clin Nephrol 1996; 46(6): 357-61
  2. Lipid lowering therapy in membranous nephropathy
    Haas M, Kerjaschki D, Mayer G
    Kidney Int 1999; 56(Suppl 71): S110-112
  3. Treatment of glomerular diseases with antioxidative therapy (Editorial)
    Haas M, Mayer G
    Wien Klin Wochenschr 2002;114/4:138-140
  4. Observing autoimmune patients may not be appropriate for testing "normal" immunoregulatory mechanisms [letter]
    Ely S ; and Haas M
    Blood 2002; 100(8):3055a-3056a.
  5. Renal Osteodystrophy
    Haas M
    Wien Med Wochenschr. 2004;154(5-6):107-18
  6. Therapeutische Implikationen der genetischen Variabilität im ACE-Gen
    Dimopoulos-Xicki  L und Haas M
    Wien Med Wochenschr 2005; 155(3-4):50-53
  7. The effect of kidney transplantation on bone. Kodras K and Haas M.
    Eur J Clin Invest 2006 ; 36 Suppl 2:63-75
  8. Haas MH. The risk of death in patients with a high coronary calcification score: does it include predialysis patients? Kidney Int 2010; 77(12):1057-9.
  9. Cejka D, Haas M. Should teriparatide ever be used for adynamic bone disease? Semin Dial 2011; 24(4):431-433.

Website by berghWerk